Please login to the form below
abatacept
This page shows the latest abatacept news and features for those working in and with pharma, biotech and healthcare.
FDA approves first drug to prevent graft-versus-host disease
BMS) arthritis drug, Orencia (abatacept).
Latest news
-
FDA to consider BMS’ Orencia for graft versus host disease
The US Food and Drug Administration has accepted a supplemental biologics licence application for Bristol Myers Squibb’s Orencia (abatacept) for the prevention of moderate-to-severe acute graft versus host
-
BMS’ Opdivo stalls in Q3, but overall figures still top expectations
Anticoagulant Eliquis (apixaban) did better than predicted with a 22% increase to $1.93bn, and there were also solid gains for arthritis and psoriasis therapy Orencia (abatacept) – up 14% to $767m –
-
Pfizer closes on EU approval of lung cancer drug Vizimpro
Bristol-Myers Squibb’s Orencia (abatacept) was backed as a second-line treatment for moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients (2 years and older), and
-
Opdivo drives growth at BMS, but US sales slow down
abatacept), which was up 16% to $625m.
-
Opdivo drives gain in BMS sales, but business revamp coming
Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.
More from news
Approximately 3 fully matching, plus 32 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2016
255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
BMS’ Brian Daniels to retire
Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Brand leaders in RA will lose market share, predict rheumatologists
leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
